A new review has been published in The Oncotarget magazine Volume 13 on November 17, 2022, titled “Myeloid-derived suppressor cells: Cancer, autoimmune diseases, and more”.
Although cancer immunotherapy using immune checkpoint inhibitors (ICI) has been recognized as one of the main treatment modalities for malignant diseases, the clinical outcome is not uniform in all cancer patients. Myeloid-derived suppressor cells (MDSCs) represent a heterogeneous population of immature myeloid cells that possess diverse strong immunosuppressive activities involving multiple immunocompetent cells and that accumulate significantly in patients who have not responded well to cancer immunotherapies .
In this new review article, researchers Masahiko Shibata, Kotaro Nanno, Daigo Yoshimori, Takahiro Nakajima, Makoto Takada, Takashi Yazawa, Kousaku Mimura, Norio Inoue, Takafumi Watanabe, Kazunoshin Tachibana, Satoshi Muto, Tomoyuki Momma, Yoshiyuki Suzuki, Koji Kono, Shungo Endo and Seiichi Takenoshita. from Fukushima Medical University, Aizu Chuo Hospital, Aizu Oncology Consortium, Nippon Medical School, and Bange Kousei General Hospital reviewed the perspective of MDSCs with emerging evidence.
“Here, we review the following: the phenotypes and origins of MDSCs; mechanisms of immunosuppression by MDSCs; the functions of MDSCs in the TME; MDSCs in Benign Disorders and Physiology; and considering the manipulation of MDSCs in the treatment of cancer. »
Many studies on CSMDs have been performed in malignant diseases. Substantial studies on the involvement of CSMDs in non-malignant diseases such as chronic infections and autoimmune diseases, as well as physiological roles in obesity, aging, pregnancy and newborns, have yet to be done. reported. Physiological roles in obesity, aging, pregnancy and newborns have not yet been reported. With the growing understanding of the roles of CSDMs, variable therapeutic strategies and agents targeting CSDMs are being studied, some of which have been used in clinical trials. Further studies are needed to develop more effective strategies against CSMD.
ICI therapies have been developed and have shown surprising results in many types of cancer. However, the effects of ICIs are not universal or uniform in all cancer patients, and emerging evidence has indicated that MDSCs are a crucial target to overcome this important issue. With an increasing understanding of the roles of MDSCs, variable therapeutic strategies and agents targeting MDSCs are being explored, some of which have been used in clinical trials.
“Further studies are needed for the development of more effective strategies against MDSCs.”
Source :
Journal reference:
Shibata, M., et al. (2022) Myeloid-derived suppressor cells: Cancer, autoimmune diseases and others. Oncotarget. doi.org/10.18632/oncotarget.28303.